Why Moderna and Merck Are Avoiding the Word ‘Vaccine’ for a Promising Cancer Shot

The science has not changed, but the vocabulary has

One of the more revealing biotechnology stories of 2026 is not only about what a treatment does. It is about what companies are willing to call it. According to the supplied source text from MIT Technology Review, Moderna and Merck are advancing a highly promising personalized mRNA-based cancer shot while avoiding the word “vaccine” in formal communications. Instead, they describe it as an individualized neoantigen therapy, or INT.

That shift is not merely semantic. It reflects a political and regulatory environment in which the term “vaccine” has become a liability for some companies, even when it remains scientifically appropriate.

How the treatment works

The basic mechanism described in the source is clear. Moderna sequences a patient’s cancer cells to identify neoantigens, the unusual molecules on the tumor surface. It then packages the genetic code for those neoantigens into a shot. The goal is to train the immune system to recognize and destroy cells carrying those markers.

By function, that is a vaccine-like process. The patient is being immunized against a target. The target is cancer rather than a virus, but the logic is recognizably similar to mRNA vaccination used in infectious disease. The source text makes that comparison directly, noting that mechanistically the approach is similar to the Covid-19 vaccines.

Why the wording changed

Moderna has not called the shot a cancer vaccine in formal communications since 2023, according to the source. That was the year it partnered with Merck and rebranded the program as individualized neoantigen therapy. At the time, Moderna’s chief executive said the new terminology better described the program’s goal. The explanation is not baseless. A therapy is given to someone who already has cancer, not to a healthy population to prevent infection.

But the supplied article makes clear that politics also sits behind the renaming. Moderna’s broader vaccine ambitions have run into hostility from vaccine skeptics in the federal government. The source says Robert F. Kennedy Jr., as head of the Department of Health and Human Services, unwound support for dozens of mRNA-related projects, including a $776 million award to Moderna for a bird flu vaccine. By January, the company was warning that it might have to stop late-stage infectious-disease vaccine programs altogether.

In that climate, language starts to matter in a new way. Calling something a vaccine may invite opposition that a company wants to avoid, even if the underlying science fits the term.

A breakthrough under a safer label

The treatment’s promise is part of what makes this naming struggle so consequential. The source text says Moderna and Merck showed this year that the shot halved the chance that patients with the deadliest form of skin cancer would die from a recurrence after surgery. That is the kind of result that would ordinarily fuel excitement around a new class of cancer vaccines. Instead, the companies are walking carefully around the term.

This is where the story extends beyond one product. When a scientifically accurate word becomes politically expensive, firms adapt. Branding turns defensive. Communications become strategic. The result is that public understanding may become less clear precisely when the science is becoming more significant.

The industry is adjusting with Moderna

The change is not limited to one company. The source text says BioNTech has also shifted its language, moving from “neoantigen vaccine” in 2021 to “mRNA cancer immunotherapies” in a more recent report. That suggests a broader industry recalibration rather than an isolated choice. If multiple developers are softening or replacing the word “vaccine,” the move likely reflects shared political and commercial calculations.

That does not mean the companies are misrepresenting the treatment. “Therapy” is not wrong. The issue is that it is incomplete as an explanation of why the treatment works. If the public hears only that it is a therapy, some of the conceptual power of the approach disappears. This is not just treatment; it is immune instruction tailored to a patient’s tumor biology.

Language is becoming part of the market environment

Biotechnology companies have always paid close attention to labels because labels shape regulators, investors, clinicians, and patients. But the Moderna case shows a new level of pressure. Vocabulary is no longer only about precision or marketing. It is about political survivability.

That matters because mRNA remains one of the most important platform technologies in medicine. If companies decide certain words are too risky to use, even for successful products, the language of public health and cancer treatment may begin to drift away from scientific clarity and toward strategic ambiguity.

The supplied article frames this as a “vocabulary paradox,” and that is the right description. Moderna and Merck appear to be advancing a treatment that behaves like a vaccine, works through immunization logic, and could represent a genuine breakthrough. Yet in the current climate, calling it a vaccine may be the one thing they most want to avoid.

This article is based on reporting by MIT Technology Review. Read the original article.